Interim Safety and Effectiveness Results From a 5-Year Observational Study of Deferasirox in Pediatric Patients Aged 2–<6 Years At Enrollment

Abstract 2125 Young children typically receive more blood transfusions per kg body weight compared with adults, increasing the risk of iron overload. Iron overload may lead to endocrine abnormalities that can affect growth and development. Data from clinical trials of the iron chelator deferasirox (...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2012-11, Vol.120 (21), p.2125-2125
Main Authors: Vichinsky, Elliott, El-Beshlawy, Amal, Alzoebie, Azzam, Bernaudin, Francoise, Koussa, Suzanne, Chotsampancharoen, Thirachit, El-Ali, Ali, Arrowsmith, Caroline, Martin, Nicolas, El-Alfy, Mohsen
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract 2125 Young children typically receive more blood transfusions per kg body weight compared with adults, increasing the risk of iron overload. Iron overload may lead to endocrine abnormalities that can affect growth and development. Data from clinical trials of the iron chelator deferasirox (Exjade®) have demonstrated tolerability and efficacy in transfused patients with a range of underlying anemias. The registration clinical trials included 52 patients aged 2–
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V120.21.2125.2125